The Latest Information about i-FACTOR and Cerapedics

Cerapedics receives CE mark and TGA listing for new i-FACTOR™ Flex FR Biologic Bone Graft

Proven P-15 bone graft technology now features enhanced handling with addition of purified silk fibers

Find out more

Novel i-FACTOR Biologic Bone Graft Shown to improve clinical outcomes in ALIF procedures

Results from the first prospective clinical study of i-FACTOR bone graft in anterior lumbar interbody fusion surgery published in the Journal of Neurosurgery: Spine

Find out more

Cerapedics files premarket approval application with US FDA for i-FACTOR™ Peptide Enhanced Bone Graft

Application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures

Find out more

Cerapedics announces closing of venture debt loan from GE Capital

Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.

Find out more

Cerapedics announces positive results from IDE clinical trial

Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.

Find out more

Cerapedics to present preliminary outcomes data From i-FACTOR Bone Graft Study at Canaccord Genuity Musculoskeletal Conference

Cerapedics today that preliminary outcomes data from the company's FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft will be presented at the Canaccord Genuity Muscul…

Find out more